| Ytd | 186.00% | |
| 1y | 4.97% |
| Open | 27.15 | Prev Close | 26.10 | Low | 25.66 | High | 27.15 | Mkt Cap | 68.32M |
| Vol | 21.65K | Avg Vol | 131.88K | EPS | -0.94 | P/E | -27.66 | Forward P/E | -1.79 |
| Beta | 2.47 | Short Ratio | 1.54 | Inst. Own | 23.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 29.08 | 200-d Avg | 18.22 | 1yr Est | 3.60 |
CUE News
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopha
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopha
Gainers Aditxt (NASDAQ:ADTX) shares increased by 151.6% to $0.05 during Tuesday's regular sessi
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launche
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therape
Moves designed to strengthen leadership and financial position, advance portfolio, and leverage expe
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on
Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph
Cue Biopharma (NASDAQ: CUE) held its annual meeting of stockholders virtually, with Interim Presiden
The biopharmaceutical company is developing injectable biologics to selectively engage and modulate
GAME stock rose 52.3% in pre-market trading after reporting positive EBITDA and financials. Other ga
Preclinical milestone for selection and approval of first compound for lead optimization has been ac
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammato
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph
Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, F
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage bioph
In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept